The Legal 500 US Recognizes Antitrust Lawyers Hollis Salzman, Bernard Persky and Kellie Lerner
June 4, 2013
NEW YORK (June 4, 2013) – Robins, Kaplan, Miller & Ciresi L.L.P. is pleased to announce that Hollis Salzman, Bernard Persky and Kellie Lerner are recognized for their achievements in antitrust litigation, and Ms. Salzman is honored as a Leading Lawyer, in the category, “Mass tort and class action: plaintiff representation – antitrust” in The Legal 500 United States 2013.
The Legal 500 United States 2013 guide notes that:
“Salzman is ‘bright’ and ‘knowledgeable’, Persky is ‘a very impressive lawyer who brings his considerable intellect to bear on his clients’ problems’… Kellie Lerner is also recommended.”
Ms. Salzman is Co-Chair of the firm’s Antitrust and Trade Regulation Group. She has extensive antitrust experience and is nationally recognized as one of the leading antitrust litigators in the country. Ms. Salzman has particular depth of experience prosecuting antitrust violations against international cartelists. Her many accomplishments in this area include In re Air Cargo Shipping Services Antitrust Litigation (almost $500 million in partial settlements from certain defendants to date); In re Lorazepam & Clorazepate Antitrust Litigation ($135.4 million settlement); In re Buspirone Antitrust Litigation ($90 million settlement) and In re Puerto Rican Cabotage Antitrust Litigation ($52 million settlement). She currently serves as court appointed Co-Lead Counsel in In re Automotive Parts Antitrust Litigation, a private civil action that stems from what has been described by a government official as the largest Department of Justice criminal investigation in United States history.
Mr. Persky, of counsel in the firm’s Antitrust and Trade Regulation Group, is an accomplished litigator with more than 40 years of experience. He has played a key role in numerous high profile class actions, securing major monetary recoveries that serve to protect businesses, consumers, and the public at large. Throughout his career, Mr. Persky has litigated numerous significant antitrust class actions that have collectively resulted in recoveries well in excess of $1 billion and received high praise from the bench and the bar.
Ms. Lerner has over a decade of experience litigating high stakes antitrust actions, where she has successfully obtained nearly $100 million on behalf of her clients. Most recently, she was recognized by The New York Law Journal as a 2013 Rising Star for her accomplishments in the New York legal community. Ms. Lerner has worked on several groundbreaking antitrust cases, including serving as a member of the trial team in In re Abbott Laboratories Norvir Antitrust Litigation, which challenged Abbott's 400% price increase of a life-saving HIV medication. On the eve of trial, the team negotiated a $10 million settlement for the benefit of non-profit organizations serving individuals living with HIV/AIDS. Ms. Lerner is currently litigating In re Merck Mumps Vaccine Antitrust Litigation, in which she represents a proposed class of health care providers who allege that defendant unlawfully monopolized the United States market for mumps vaccine by falsifying test results and misrepresenting the vaccine’s efficacy.
About The Legal 500:
Founded in 1987, Legalease is a leader in the provision of legal market information, offering authoritative and in-depth analysis and commentary across a broad portfolio of publications, spanning directories, magazines, journals, textbooks and online. The Legal 500 series of guides reviews the strengths and strategies of law firms in over 90 countries in Europe, the Middle East, Asia, North and South America, and the Caribbean.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.